Preface (B.E. Maryanoff and C.A. Maryanoff).
1. Novel Antipsychotics with Unique D
2. Antiplatelet and Antithrombotic Agents: from Viper Venom Proteins, to Peptides and Peptidomimetics, to Small Organic Molecules (P.L. Barker and R.R. Webb, II).
3. Discovery and Preclinical Development of the Serotonin Reuptake Inhibitor Sertraline (W.M. Welch).
4. Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents (R.J. Snow and W.W. Bachovchin).
Volume 3 of Advances in Medicinal Chemistry is comprised of four chapters on diverse aspects of medicinal chemistry. Chapter 1 presents an account of a research program which was started to discover a novel antipsychotic agent with minimal side effects for the treatment, principally, of schizophrenia. Chapter 2 relates an account on the discovery of novel antithrombotic drugs based on the RGD motif through a rational design approach. Chapter 3 presents the medicinal chemistry and preclinical development surrounding sertraline, a very important serotonin reuptake drug for the treatment of endogenous depression. Finally, Chapter 4 gives a summary of a series of boronic acid-based immunosuppressants that operate via inhibition of dipeptidypeptidase IV.
- © Elsevier Science 1995
- 4th January 1996
- Elsevier Science
- eBook ISBN:
- Hardcover ISBN:
@qu:REVIEW: "In summary, the third volume of this series continues to offer well written, interesting accounts of topics important to the discipline of medicinal chemistry and with up-to-date references. Some of the chapters seem well suited as special topics in graduate courses. This series should appeal to a broad audience of researchers, teachers, and students". @source:Journal of American Chemical Society
Medicinal Chemistry Department, R.W. Johnson Pharmaceutical Research Institute, Springhouse, Pennsylvania, USA
Chemical Development Department, R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA